gefitinib has been researched along with Conus Medullaris Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kjellén, E; Lindén, O; Stenberg, L | 1 |
| Garrido, P; Longo, F; Olmedo, ME; Riquelme, A; Rodríguez, M | 1 |
2 other study(ies) available for gefitinib and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cervical Vertebrae; Cetuximab; Chordoma; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Spinal Cord Compression | 2009 |
Long-term survival in a smoking caucasian male patient treated with gefitinib for spinal cord compression secondary to lung cancer.
Topics: Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking; Spinal Cord Compression; Survivors; Treatment Outcome | 2011 |